SAN DIEGO: #Medtech--Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, is proud to announce key milestones achieved throughout 2024, underscoring a year defined by accelerated growth, technological innovation, and meaningful clinical impact. From the widespread adoption of vMap to groundbreaking clinical data and enhanced reimbursement pathways, Vektor Medical remains steadfast in its mission to transform arrhythmia care.

Accelerated Adoption of vMap Across Arrhythmia Types

In 2024, vMap demonstrated significant clinical uptake across both new and existing sites, proving its unique value and utility in a market flooded with innovative technologies. Adoption in Atrial Fibrillation (AF) and Atrial Flutter (AFL) cases accounted for 46% of all vMap usage. The top three arrhythmias – AF, Premature Ventricular Contractions (PVC), and Ventricular Tachycardia (VT) – comprised the majority of total cases, reflecting robust growth and broad utility across arrhythmia types.

Clinical Evidence & Industry Recognition Reinforces vMap’s Impact

Significant clinical studies in 2024 further validated vMap’s role in advancing arrhythmia care:

• Data Presented at AF Symposium: vMap-guided AF driver localization and ablation achieved 86.5% freedom from all atrial arrhythmias, compared to 48.0% in the control arm (p<0.01). This reinforces vMap’s role as a powerful tool to support AF ablation.
• VT Source Differentiation Study: A study of 136 episodes from 72 patients demonstrated vMap’s 91.1% accuracy and 97.1% sensitivity, far surpassing the leading visual ECG methods (62.5% accuracy).
• Peer-Reviewed vMap Time Study: Published in the Journal of Cardiovascular Electrophysiology, this study highlighted vMap’s efficiency and efficacy in arrhythmia mapping.
• Pioneering Multimodal Innovation at HRX: HRX showcased Vektor’s potential multimodal capabilities, currently under development, earning recognition with 2 of the Top 5 Abstracts for our product innovation. Combining imaging AI with 12-lead ECG, presentations demonstrated vMap’s ability to deliver personalized insights and further advance precision medicine in arrhythmia care.

Reimbursement Milestone: Category III CPT Code and APC Assignment

A significant achievement for the year was securing a Category III CPT Code 0897T for vMap’s noninvasive arrhythmia analysis, enabling reimbursement for vMap, effective July 1, 2024. This milestone, paired with an APC assignment, marks a pivotal step in recognizing vMap's clinical and economic value.

Faster, More Advanced and More Comprehensive Mapping

Throughout the year, vMap’s capabilities were enhanced to streamline workflows, improve usability, and deliver meaningful clinical value. Key product milestones included:

• Optimized mapping processes, improving speed by up to 2x.
• Expanded ventricular mapping capabilities, including classification of endo-vs epicardial sources.
• Broader accessibility and improved workflow integration to optimize outcomes across diverse healthcare settings.
• Launch of the 60-Minute Mapping Key (complementing the existing 1-hour vMap key), to support focused, rapid arrhythmia assessments optimized for pre-procedural planning in clinics.

$25 Million Series A Funding Fuels Expansion

A significant highlight of 2024 was the successful completion of a $25 million Series A funding round led by TVM Life Sciences and Solas BioVentures. This investment helped drive the scale of operations and product innovation and expand access to vMap.

Looking Ahead

“The milestones of 2024 reflect the dedication and collaboration of our team, partners, and supporters,” said Rob Krummen, CEO of Vektor Medical. “We remain committed to driving innovation, improving patient outcomes, and empowering clinicians worldwide with smarter, faster solutions to support arrhythmia care.”

For more information on Vektor Medical and vMap, visit www.vektormedical.com and connect on LinkedIn and X.

About Vektor Medical

Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-powered, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit www.vektormedical.com.

Fonte: Business Wire